AR092347A1 - Derivados de azaindol - Google Patents
Derivados de azaindolInfo
- Publication number
- AR092347A1 AR092347A1 ARP130102427A ARP130102427A AR092347A1 AR 092347 A1 AR092347 A1 AR 092347A1 AR P130102427 A ARP130102427 A AR P130102427A AR P130102427 A ARP130102427 A AR P130102427A AR 092347 A1 AR092347 A1 AR 092347A1
- Authority
- AR
- Argentina
- Prior art keywords
- independently selected
- alkyl
- hydrogen
- haloalkyl
- halo
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/10—Spiro-condensed systems
- C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Dermatology (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Rheumatology (AREA)
- Transplantation (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pain & Pain Management (AREA)
- Vascular Medicine (AREA)
- Otolaryngology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Reivindicación 1: Un compuesto de la fórmula (1), o una de sus sales farmacéuticamente aceptable, donde: R¹ se selecciona entre cicloalquilo C₃₋₈, heterociclilo C₂₋₆, arilo C₆₋₁₄, y heteroarilo C₁₋₉, cada uno de los cuales está opcionalmente sustituido con entre uno y cinco sustituyentes que se seleccionan, de manera independiente, entre halo, oxo, -CN, R¹¹, y R¹²; cada uno de R², R⁴, y R⁵ se selecciona, de manera independiente, entre hidrógeno, halo, -OH, -CN, alquilo C₁₋₃, y haloalquilo C₁₋₃; R³ se selecciona entre hidrógeno, alquilo C₁₋₃, y haloalquilo C₁₋₃; cada uno de R⁶ y R⁷ se selecciona, de manera independiente, entre hidrógeno, alquilo C₁₋₃, y haloalquilo C₁₋₃; R⁸ se selecciona de hidrógeno, metilo, y -NH₂; R⁹ se selecciona entre hidrógeno, halo, -CN, haloalquilo C₁₋₃, -OR¹⁶, -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)N(R¹⁶)R¹⁷, -C(O)N(R¹⁶)OR¹⁷, -C(O)N(R¹⁶)S(O)₂R¹⁸, -SR¹⁶, -S(O)R¹⁸, -S(O)₂R¹⁸, y -S(O)₂N(R¹⁶)R¹⁷; o R⁸ se selecciona entre -NH- y -CH₂-, y R⁸ y R⁹, junto con los átomos de carbono a los cuales están unidos, forman un heteroarileno C₂₋₄ que tiene 5 átomos en el anillo y entre 1 y 3 heteroátomos, cada uno de los heteroátomos es nitrógeno, y donde el heteroarileno C₂₋₄ está opcionalmente sustituido con R¹²; R¹⁰ se selecciona entre halo, -OH, alquilo C₁₋₃, -NHR¹⁶, y -NHC(O)R¹⁶; cada R¹¹ se selecciona, de manera independiente, entre -OR¹³, -N(R¹³)R¹⁴, -NR¹³C(O)R¹⁴, -NHC(O)NR¹³R¹⁴, -NR¹³C(O)NHR¹⁴, -C(O)R¹³, -C(O)OR¹³, -C(O)N(R¹³)R¹⁴, -C(O)N(R¹³)OR¹⁴, -C(O)N(R¹³)S(O)₂R¹², -N(R¹³)S(O)₂R¹², -SR¹³, -S(O)R¹², -S(O)₂R¹², y -S(O)₂N(R¹³)R¹⁴; cada R¹² se selecciona, de manera independiente, entre alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₈-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno de los cuales está opcionalmente sustituido con entre uno y cinco sustituyentes que se seleccionan, de manera independiente, entre halo, oxo, -CN, alquilo C₁₋₆, haloalquilo C₁₋₆ y R¹⁵; cada R¹³ y R¹⁴ se selecciona, de manera independiente, entre (a) hidrógeno; y (b) alquilo C₁₋₆, alquenilo C₂₋₆, alquinilo C₂₋₆, cicloalquilo C₃₋₆-(CH₂)ₘ-, arilo C₆₋₁₄-(CH₂)ₘ-, heterociclilo C₂₋₆-(CH₂)ₘ-, y heteroarilo C₁₋₉-(CH₂)ₘ-, cada uno de los cuales está opcionalmente sustituido con entre uno y cinco sustituyentes que se seleccionan, de manera independiente, entre halo, oxo, -CN, alquilo C₁₋₆, haloalquilo C₁₋₆ y R¹⁵; cada R¹⁵ se selecciona, de manera independiente, entre -OR¹⁶, -N(R¹⁶)R¹⁷, -N(R¹⁶)C(O)R¹⁷, -NHC(O)NR¹⁶R¹⁷, -NR¹⁶C(O)NHR¹⁷, -C(O)R¹⁶, -C(O)OR¹⁶, -C(O)N(R¹⁶)R¹⁷, -C(O)N(R¹⁶)OR¹⁷, -C(O)N(R¹⁶)S(O)₂R¹⁸, -NR¹⁶S(O)₂R¹⁸, -SR¹⁶, -S(O)R¹⁸, -S(O)₂R¹⁸, y -S(O)₂N(R¹⁶)R¹⁷; cada R¹⁶ y R¹⁷ se selecciona, de manera independiente, entre hidrógeno, alquilo C₁₋₆, y cicloalquilo C₃₋₆; cada R¹⁸ se selecciona, de manera independiente, entre alquilo C₁₋₆ y cicloalquilo C₃₋₆; cada m se selecciona, de manera independiente, entre 0, 1, 2, 3 y 4; donde cada una de las fracciones de heteroarilo mencionadas tiene, de manera independiente, 1 a 4 heteroátomos que se seleccionan de manera independiente de N, O, y S, y cada una de las fracciones heterociclilo mencionadas tiene independientemente 1 a 4 heteroátomos que se seleccionan de manera independiente de N, O y S.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261670116P | 2012-07-10 | 2012-07-10 |
Publications (1)
Publication Number | Publication Date |
---|---|
AR092347A1 true AR092347A1 (es) | 2015-04-15 |
Family
ID=48795966
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP130102427A AR092347A1 (es) | 2012-07-10 | 2013-07-08 | Derivados de azaindol |
Country Status (26)
Country | Link |
---|---|
US (2) | US8835420B2 (es) |
EP (1) | EP2872507A1 (es) |
JP (1) | JP2015522074A (es) |
KR (1) | KR20150031334A (es) |
CN (1) | CN104619708A (es) |
AP (1) | AP2015008236A0 (es) |
AR (1) | AR092347A1 (es) |
AU (1) | AU2013288895A1 (es) |
BR (1) | BR112015000386A2 (es) |
CA (1) | CA2878502A1 (es) |
CO (1) | CO7280475A2 (es) |
CR (1) | CR20150056A (es) |
DO (1) | DOP2015000002A (es) |
EA (1) | EA201590183A1 (es) |
HK (1) | HK1210771A1 (es) |
IL (1) | IL236535A0 (es) |
MA (1) | MA37831B1 (es) |
MX (1) | MX2015000107A (es) |
NZ (1) | NZ704160A (es) |
PE (1) | PE20150754A1 (es) |
PH (1) | PH12015500063B1 (es) |
SG (1) | SG11201500063UA (es) |
TN (1) | TN2015000005A1 (es) |
TW (1) | TW201414734A (es) |
UY (1) | UY34893A (es) |
WO (1) | WO2014011568A1 (es) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EA031153B1 (ru) * | 2011-06-10 | 2018-11-30 | Мерк Патент Гмбх | Применение пиримидиновых соединений с btk ингибирующей активностью |
UY35945A (es) * | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
WO2015106014A1 (en) * | 2014-01-09 | 2015-07-16 | Takeda Pharmaceutical Company Limited | Azaindole derivatives |
WO2016064957A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Bicyclic heteroaryl amine compounds as pi3k inhibitors |
WO2016064958A1 (en) | 2014-10-22 | 2016-04-28 | Bristol-Myers Squibb Company | Heteroaryl substituted pyrrolotriazine amine compounds as pi3k inhibitors |
US9997391B2 (en) * | 2015-10-19 | 2018-06-12 | QROMIS, Inc. | Lift off process for chip scale package solid state devices on engineered substrate |
WO2017079542A1 (en) * | 2015-11-04 | 2017-05-11 | Merck Patent Gmbh | Methods for treating cancer using pyrimidine and pyridine compounds with btk inhibitory activity |
FI3377484T3 (fi) * | 2015-11-17 | 2023-11-30 | Merck Patent Gmbh | Menetelmiä multippeliskleroosin hoitoon käyttämällä pyrimidiini- ja pyridiiniyhdisteitä, joilla on BTK inhiboiva vaikutus |
US10792283B2 (en) * | 2016-03-05 | 2020-10-06 | Hangzhou Zhengxiang Pharmaceuticals Co., Ltd. | Quinoline analogs as phosphatidylinositol 3-kinase inhibitors |
US10755986B2 (en) * | 2016-03-29 | 2020-08-25 | QROMIS, Inc. | Aluminum nitride based Silicon-on-Insulator substrate structure |
CN107964018A (zh) * | 2016-10-19 | 2018-04-27 | 中国人民解放军军事医学科学院毒物药物研究所 | 取代嘌呤酮类衍生物及其医药用途 |
CA3142088C (en) * | 2019-05-08 | 2023-02-28 | Tyk Medicines, Inc. | Compound used as kinase inhibitor and application thereof |
CN112794851B (zh) * | 2021-01-26 | 2022-08-23 | 复旦大学 | 3-(吡啶-3基)-7-氮杂吲哚衍生物PI3Kδ抑制剂及其制备方法与应用 |
Family Cites Families (33)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5376645A (en) | 1990-01-23 | 1994-12-27 | University Of Kansas | Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof |
KR0166088B1 (ko) | 1990-01-23 | 1999-01-15 | . | 수용해도가 증가된 시클로덱스트린 유도체 및 이의 용도 |
GB9518953D0 (en) | 1995-09-15 | 1995-11-15 | Pfizer Ltd | Pharmaceutical formulations |
GB9711643D0 (en) | 1997-06-05 | 1997-07-30 | Janssen Pharmaceutica Nv | Glass thermoplastic systems |
US6187777B1 (en) | 1998-02-06 | 2001-02-13 | Amgen Inc. | Compounds and methods which modulate feeding behavior and related diseases |
MXPA02010618A (es) | 2000-04-25 | 2004-05-05 | Icos Corp | Inhibidores de fosfatidilinositol 3-quinasa delta. |
US6667300B2 (en) | 2000-04-25 | 2003-12-23 | Icos Corporation | Inhibitors of human phosphatidylinositol 3-kinase delta |
US20020183292A1 (en) | 2000-10-31 | 2002-12-05 | Michel Pairet | Pharmaceutical compositions based on anticholinergics and corticosteroids |
US6806272B2 (en) | 2001-09-04 | 2004-10-19 | Boehringer Ingelheim Pharma Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
US7348337B2 (en) | 2002-05-28 | 2008-03-25 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic 4-alkenyl piperidine amides |
US6900206B2 (en) | 2002-06-20 | 2005-05-31 | Bristol-Myers Squibb Company | Indole, azaindole and related heterocyclic sulfonylureido piperazine derivatives |
US6861422B2 (en) | 2003-02-26 | 2005-03-01 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Dihydropteridinones, processes for preparing them and their use as pharmaceutical compositions |
CN100398545C (zh) | 2003-09-08 | 2008-07-02 | 安万特药物公司 | 噻吩并吡唑类化合物 |
DE602004010299T2 (de) | 2003-12-22 | 2008-09-18 | Memory Pharmaceuticals Corp. | Indole, 1h-indazole, 1,2-benzisoxazole und 1,2-benzisothiazole und deren herstellung und anwendungen |
EP1742944B1 (en) | 2004-04-22 | 2010-11-10 | Memory Pharmaceuticals Corporation | Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof |
GB0415364D0 (en) | 2004-07-09 | 2004-08-11 | Astrazeneca Ab | Pyrimidine derivatives |
DE102004034623A1 (de) | 2004-07-16 | 2006-02-02 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Neue 6-Formyl-tetrahydropteridine, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel |
US20060035903A1 (en) | 2004-08-14 | 2006-02-16 | Boehringer Ingelheim International Gmbh | Storage stable perfusion solution for dihydropteridinones |
US7759485B2 (en) | 2004-08-14 | 2010-07-20 | Boehringer Ingelheim International Gmbh | Process for the manufacture of dihydropteridinones |
WO2006021548A1 (de) | 2004-08-27 | 2006-03-02 | Boehringer Ingelheim International Gmbh | Dihydropteridinone, verfahren zu deren herstellung und deren verwendung als arzneimittel |
DE102004058337A1 (de) | 2004-12-02 | 2006-06-14 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung von annelierten Piperazin-2-on Derivaten |
FR2878849B1 (fr) | 2004-12-06 | 2008-09-12 | Aventis Pharma Sa | Indoles substitues, compositions les contenant, procede de fabrication et utilisation |
EP2057129A1 (en) | 2006-08-24 | 2009-05-13 | AstraZeneca AB | Morpholino pyrimidine derivatives useful in the treatment of proliferative disorders |
CL2007003444A1 (es) | 2006-11-30 | 2008-06-27 | Genentech Inc | Compuestos derivados de pirrolo[3,2-c]piridina; composicion farmaceutica; y uso en el tratamiento de un trastorno hiperproliferativo o una enfermedad inflamatoria. |
EP2164850B1 (en) | 2007-06-12 | 2016-01-13 | Genentech, Inc. | N-substituted azaindoles and methods of use |
CN106279283A (zh) | 2007-08-13 | 2017-01-04 | 症变治疗公司 | 新颖的葡糖激酶活化剂 |
WO2010036380A1 (en) | 2008-09-26 | 2010-04-01 | Intellikine, Inc. | Heterocyclic kinase inhibitors |
SG175877A1 (en) | 2009-05-04 | 2011-12-29 | Plexxikon Inc | Compounds and methods for inhibition of renin, and indications therefor |
AR077267A1 (es) * | 2009-06-25 | 2011-08-17 | Amgen Inc | Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes. |
JP2012531435A (ja) | 2009-06-25 | 2012-12-10 | アムジエン・インコーポレーテツド | PI3K阻害剤としての4H−ピリド[1,2−a]ピリミジン−4−オン誘導体 |
KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Pi3k 저해물질로서의 피리미디논 |
AR085406A1 (es) | 2011-02-25 | 2013-09-25 | Takeda Pharmaceutical | Oxazinopteridinas y oxazinopteridinonas n-sustituidas |
UY35945A (es) * | 2014-01-09 | 2015-08-31 | Takeda Pharmaceutical | Derivados de azaindol |
-
2013
- 2013-07-05 UY UY0001034893A patent/UY34893A/es not_active Application Discontinuation
- 2013-07-05 TW TW102124297A patent/TW201414734A/zh unknown
- 2013-07-08 KR KR20157003555A patent/KR20150031334A/ko not_active Application Discontinuation
- 2013-07-08 JP JP2015521701A patent/JP2015522074A/ja active Pending
- 2013-07-08 PE PE2015000013A patent/PE20150754A1/es not_active Application Discontinuation
- 2013-07-08 WO PCT/US2013/049612 patent/WO2014011568A1/en active Application Filing
- 2013-07-08 EP EP13737976.4A patent/EP2872507A1/en not_active Withdrawn
- 2013-07-08 AR ARP130102427A patent/AR092347A1/es unknown
- 2013-07-08 CN CN201380043657.XA patent/CN104619708A/zh active Pending
- 2013-07-08 MX MX2015000107A patent/MX2015000107A/es unknown
- 2013-07-08 EA EA201590183A patent/EA201590183A1/ru unknown
- 2013-07-08 CA CA2878502A patent/CA2878502A1/en not_active Abandoned
- 2013-07-08 BR BR112015000386A patent/BR112015000386A2/pt not_active Application Discontinuation
- 2013-07-08 MA MA37831A patent/MA37831B1/fr unknown
- 2013-07-08 US US13/937,081 patent/US8835420B2/en not_active Expired - Fee Related
- 2013-07-08 AP AP2015008236A patent/AP2015008236A0/xx unknown
- 2013-07-08 NZ NZ704160A patent/NZ704160A/en not_active IP Right Cessation
- 2013-07-08 SG SG11201500063UA patent/SG11201500063UA/en unknown
- 2013-07-08 AU AU2013288895A patent/AU2013288895A1/en not_active Abandoned
-
2014
- 2014-08-04 US US14/451,254 patent/US20140343033A1/en not_active Abandoned
- 2014-12-31 IL IL236535A patent/IL236535A0/en unknown
-
2015
- 2015-01-07 DO DO2015000002A patent/DOP2015000002A/es unknown
- 2015-01-07 TN TNP2015000005A patent/TN2015000005A1/fr unknown
- 2015-01-09 PH PH12015500063A patent/PH12015500063B1/en unknown
- 2015-02-04 CO CO15021949A patent/CO7280475A2/es unknown
- 2015-02-06 CR CR20150056A patent/CR20150056A/es unknown
- 2015-11-19 HK HK15111423.7A patent/HK1210771A1/xx unknown
Also Published As
Publication number | Publication date |
---|---|
MA37831B1 (fr) | 2018-09-28 |
BR112015000386A2 (pt) | 2017-06-27 |
WO2014011568A1 (en) | 2014-01-16 |
US20140343033A1 (en) | 2014-11-20 |
CR20150056A (es) | 2015-05-25 |
AU2013288895A1 (en) | 2015-02-12 |
CO7280475A2 (es) | 2015-05-29 |
MA37831A1 (fr) | 2018-02-28 |
DOP2015000002A (es) | 2015-04-15 |
CN104619708A (zh) | 2015-05-13 |
US8835420B2 (en) | 2014-09-16 |
PH12015500063A1 (en) | 2015-03-02 |
KR20150031334A (ko) | 2015-03-23 |
CA2878502A1 (en) | 2014-01-16 |
EA201590183A1 (ru) | 2015-06-30 |
JP2015522074A (ja) | 2015-08-03 |
AP2015008236A0 (en) | 2015-01-31 |
MX2015000107A (es) | 2015-04-14 |
TW201414734A (zh) | 2014-04-16 |
EP2872507A1 (en) | 2015-05-20 |
PE20150754A1 (es) | 2015-05-15 |
NZ704160A (en) | 2017-01-27 |
TN2015000005A1 (en) | 2016-06-29 |
PH12015500063B1 (en) | 2015-03-02 |
HK1210771A1 (en) | 2016-05-06 |
UY34893A (es) | 2014-02-28 |
SG11201500063UA (en) | 2015-03-30 |
US20140018344A1 (en) | 2014-01-16 |
IL236535A0 (en) | 2015-02-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR092347A1 (es) | Derivados de azaindol | |
AR095198A1 (es) | Derivados de triazolona de piridinilo y piridinilo fusionado | |
AR092742A1 (es) | Piridinonas antifibroticas | |
AR103297A1 (es) | Pirrolo y pirazolopirimidinas como inhibidores de la proteasa 7 específica de ubiquitina | |
AR102492A1 (es) | Cromanos sustituidos y métodos para su uso | |
AR103252A1 (es) | Compuestos de quinazolina | |
AR094299A1 (es) | Derivados de ftalazin-1(2h)-ona sustituidos | |
AR091424A1 (es) | Compuestos triciclicos sustituidos como inhibidores de receptores del factor de crecimiento del fibroplasto (fgfr) | |
AR102177A1 (es) | Compuestos de heteroarilo como inhibidores de btk y usos de los mismos | |
AR111407A1 (es) | Compuestos inhibidores de ask1 y usos de los mismos | |
AR103969A1 (es) | Inmunomoduladores | |
AR098872A1 (es) | Moduladores de tetrahidropiridopirazinas de gpr6 | |
AR100809A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR097571A1 (es) | Compuestos espirocíclicos como inhibidores de la triptofano hidroxilasa | |
AR100808A1 (es) | Inhibidores de fosfatidilinositol 3-quinasa | |
AR096979A1 (es) | Derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
AR106301A1 (es) | Composiciones de pirrolpirimidina como inhibidores de quinasas | |
AR095359A1 (es) | Compuestos heteroaromáticos y su uso como ligandos d1 de dopamina | |
AR104878A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR099890A1 (es) | Inhibidores de histona demetilasas | |
AR112907A1 (es) | Pirazoles inhibidores de monoacilglicerol lipasa (magl) | |
AR104879A1 (es) | MODULADORES DE ROR GAMMA (RORg) | |
AR095136A1 (es) | Derivados de pirazol microbiocidas | |
AR107321A1 (es) | Compuestos antiproliferativos, y sus composiciones farmacéuticas y usos | |
AR101077A1 (es) | Triterpenoides con actividad inhibidora de la maduración de hiv |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |